How will we sequence ALK inhibitors in 5
´
years
time?
“
Future
” approach
Crizotinib
Ceritinib
Alectinib
Lorlatinib?
Alectinib
Address resistance as it occurs or prevent resistance by using new molecules?
When to switch therapy based on clinical or molecular readouts?
Lorlatinib
INDICACIÓN NO APROBADA, EN INVESTIGACIÓN
